Artificial intelligence in bioinformatics: from hype to sustained acceleration in drug development

The evolution of AI in bioinformatics

While bioinformatics has traditionally focused on analysing complex biological datasets, AI makes it possible to identify patterns and relationships that were previously beyond the reach of conventional analytical methods. Machine learning, deep learning and generative AI expand the capacity to interpret vast volumes of genomic, transcriptomic and proteomic data, accelerating the discovery of new biological insights.

As a result, AI is evolving from a supporting analytical tool into an integral component of the entire research and development value chain, from target identification and lead optimisation to biomarker development and patient selection in clinical trials.

Accelerating drug development

Developing new medicines is a lengthy and costly process in which a significant proportion of candidate molecules ultimately fail. AI helps organisations make this process more efficient and targeted by supporting better decisions at earlier stages of development.

Applications of AI in bioinformatics include:

• Identifying new therapeutic targets;

• Predicting protein structures and molecular interactions;

• Discovering biomarkers for precision medicine;

• Stratifying patients in clinical trials;

• Integrating multi-omics datasets;

• Predicting safety and efficacy profiles.

By revealing complex biological relationships more rapidly, AI enables researchers to test hypotheses more strategically, identify development risks earlier and prioritise research programmes more effectively.

AI is only as strong as the quality of its data

Despite rapid technological progress, one principle remains unchanged: AI creates value only when the underlying data are reliable, representative and well organised.

Biological datasets are often heterogeneous, originate from multiple sources and are collected using different protocols. Without consistent data quality, clear governance and reproducible analytical methods, the risk of unreliable models and incorrect conclusions increases significantly.

Successful AI implementations therefore do not begin with algorithms. They begin with a solid data foundation centred on quality, transparency and validation.

Human expertise remains decisive

Although AI continues to become more powerful, technology does not replace scientific expertise. On the contrary, as algorithms become more complex, experienced bioinformaticians, computational biologists and data scientists become increasingly important. These professionals must be able to interpret results critically and place them in the correct biological context.

The most valuable insights emerge when computational models are combined with in-depth knowledge of disease biology, drug development and clinical practice. It is this interaction between people and technology that makes AI a strategic instrument rather than an isolated technological solution.

From experimentation to enterprise-wide impact

Many AI initiatives begin as standalone proofs of concept, but only a limited number of organisations succeed in scaling them sustainably. The greatest challenge is not developing new algorithms, but creating an organisation in which AI becomes an enduring part of decision-making and innovation.

This requires multidisciplinary collaboration between biologists, clinicians, software engineers, data scientists and bioinformaticians. It must be supported by scalable infrastructure, clear governance and a culture centred on data and scientific validation.

Organisations that invest in these capabilities not only strengthen their capacity for innovation, but also build a lasting competitive advantage in an increasingly data-intensive sector.